SYS-CON MEDIA Authors: Peter Silva, Kevin Jackson, Jessica Qiu, Dana Gardner, Dan Stolts

News Feed Item

Blood-Brain Barrier Technologies and Global Markets

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Blood-Brain Barrier Technologies and Global Markets

http://www.reportlinker.com/p0492943/Blood-Brain-Barrier-Technologies-and-Global-Markets.html

This BCC Research report analyzes the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its growth potential, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are also discussed. This report offers an outlook of the technology's potential that is on the verge of rapid increase.

Use this report to:
- Determine the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its growth potential over a five-year period from 2014
through 2019.
- Receive information about the key drivers and key challenges involved in BBB technologies.
- Receive information about the promising CNS drugs that are in the later stage of the development pipeline for potential use with BBB technology.
- Learn about key BBB technology patents.

Highlights
- The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.
- Receptor mediated transport is the largest segment of the global BBB market and is projected to increase from about $38.7 million in 2014 to $456 million by 2019, with a CAGR of 63.8% for the period of 2014 to 2019.
- Carrier-mediated transport (CMT) is an emerging technology that is expected to reach $15.5 million by 2019.

INTRODUCTION

STUDY GOALS AND OBJECTIVES
BCC Research's goal in conducting this study was to determine the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its
growth potential over a five-year period from 2014 through 2019. Our key objective was to present a comprehensive analysis of the current BBB technology and drug
development market and its future direction, with the aim to first define and classify that technology as it pertains to therapeutics in which the technology enables the
therapeutic to directly cross rather than bypass the BBB.

REASONS FOR DOING THIS STUDY
BBB technologies are poised to open up a vast untapped potential in the growing central nervous system therapeutic market, where today growth is limited by the
complexity of this layer in the brain that prevents the passage of many potentially useful molecules/compounds. This report offers an outlook of the technology's potential that is on the verge of rapid increase. Therapeutics make up the main area of investment related to this technology — and the main focus of this report. BCC Research has not yet examined the BBB, although the central nervous system has been a consistent focus. As such, this snapshot and study of trending and growth is unique.

SCOPE OF REPORT
The scope of this study encompasses companies that develop technologies to enable the crossing of the BBB and drug development, in which a quality of the development
is enabling the crossing of the BBB, where passage was previously impossible often due to size. BCC Research analyzes each technology, determines its current market
status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.

INTENDED AUDIENCE
In the report, the various BBB technologies are defined and given their history in medicine. The report also looks at the types and technology categories, major companies, impact on the pharmaceutical market, applications, current market values, growth potential and significant trends. This study will be of interest to the biotechnology and pharmaceutical industries and related life sciences, analytics, drug discovery, and diagnostic test manufacturing companies, as well as all those interested or actively working in drug and imaging agent research and investors in all of the above.

METHODOLOGY
BCC Research presents an analysis of the types of technologies, applications, and therapeutic areas representing financial value in the area of BBB technology in medicine as it relates primarily to drug discovery, development, and commercialization. Estimated values are based on actual aggregate sales for the years discussed. Overall, information is compiled through a combination of primary and secondary research, including annual reports and interviews with company officials.

INFORMATION SOURCES
BCC Research's analysis includes the review of more than 50 companies and information from financial and trade publications, as well as the US Food and Drug Administration (FDA). Pharmaceutical and biotechnology companies, as well as support companies, are also included.
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 2
METHODOLOGY 3
INFORMATION SOURCES 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 3
BCC RESEARCH WEBSITE 3
DISCLAIMER 4
CHAPTER 2 EXECUTIVE SUMMARY 6
SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
THROUGH 2019 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
2012-2019 ($ MILLIONS) 7
EMERGING BBB TECHNOLOGY MARKET 10
KEY DRIVERS 12
KEY CHALLENGES 13
CHAPTER 3 OVERVIEW 15
MAJOR TRENDS 15
TODAY'S PHARMA MARKET 16
TABLE 1 PHARMACEUTICAL DRUGS MARKET BY GEOGRAPHICAL REGION,
THROUGH 2017 ($ BILLIONS) 17
FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND
2017 (PERCENT OF GLOBAL SALES) 18
FIGURE 2 EMERGING REGIONS' PHARMACEUTICAL MARKET SHARES COMPARED TO
THE U.S. AND EUROPE, 2017 (ESTIMATED $BILLIONS) 18
FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY
REGION, 2019* ($ MILLIONS) 19
FIGURE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY
THERAPEUTIC AREA, 2019* (% OF ALL SALES FROM COMMERCIALIZED DRUGS) 20
FIGURE 5 MOST FREQUENT BBB TARGET AREAS FOR COMPANIES WITH DRUGS IN
CLINICAL DEVELOPMENT, 2019* (%) 21
BIOLOGICS 22
TABLE 2 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY,
2013 22
GENERICS SIGNAL NEED FOR INNOVATION 24
NEUROFOCUSING IN THE PHARMA INDUSTRY 24
FIGURE 6 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2012 ($ BILLIONS) 24
TABLE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH
2019 (NUMBER OF UNITS COMMERCIALIZED) 26
TABLE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY
POSSIBLE CNS INDICATION, 2014 AND 2019 (NUMBER OF UNITS PER INDICATION) 26
TABLE 5 TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS) 27
EMERGING BBB TECHNOLOGY MARKET 28
BRIEF HISTORY OF BBB 29
BLOOD BRAIN BARRIER DEFINED 29
BBB COMPONENTS 30
Pericytes 30
Tight Junctions 31
Lipid Barrier 31
Enzymatic Barrier 31
Efflux Pumps 31
BBB ILLUSTRATED 31
FIGURE 7 PARTS OF THE BBB 31
MAIN AREAS OF THE BRAIN 32
FIGURE 8 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS 32
TREATING DISEASE AND THE BBB 34
MENINGITIS 34
MULTIPLE SCLEROSIS (MS) 34
ENCEPHALITIS 35
ALZHEIMER'S DISEASE (AD) 35
PARKINSON'S DISEASE (PD) 36
BBB TECHNOLOGY CLASSIFICATION 37
MOST COMMON BBB TECHNOLOGY 37
CHALLENGES WITH THE MOST COMMON TECHNOLOGY USED 38
TRANSPORT CONSIDERATIONS 39
Bypassing the BBB 39
BBB TECHNOLOGY DETAILED 39
Chemical Transport Systems 40
Biological Carrier or Transport Systems 40
Physical Force (Energetic) Opening Through Sound Waves (Targeted
Ultrasound) 41
Enhancing Biological Transport System Techniques 42
FIGURE 9 METHODS OF CROSSING THE BBB 42
Nanoparticles and Liposomes 43
Nanoparticles 43
TABLE 6 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY 44
Challenges with Nanoparticles 45
Liposomes 45
PATENTS AND INTELLECTUAL PROTECTION 47
TABLE 7 KEY BBB TECHNOLOGY PATENTS 48
ArmaGen's Patent Estate 50
Life After Patenting 53
TABLE 8 SAMPLE OF FINANCIAL DEALS IN CNS THERAPEUTICS IN THE FIVE YEARS
ENDING 2013 54
BBB TECHNOLOGY MARKET: PRESENT AND FUTURE 54
TABLE 9 SAMPLE OF FINANCIAL DEALS IN BBB TECHNOLOGY RECEIVED THROUGH
PHARMACEUTICAL COMPANY (ESTIMATED, $ MILLIONS) 55
FIGURE 10 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY TECHNOLOGY TYPE,
2014* (% OF INDUSTRY) 56
FIGURE 11 COMPOSITION OF BBB TECHNOLOGY BY TECHNOLOGY TYPE IN THE
COMMERCIALIZED (THERAPEUTIC DRUG) MARKET, 2019 (% OF MARKET) 56
TABLE 10 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND
2019 (NUMBER OF UNITS) 58
FIGURE 12 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014
AND 2019 (NUMBER OF UNITS) 58
TABLE 11 BBB TECHNOLOGY COMPANIES AND RESPECTIVE TECHNOLOGICAL
METHOD 59
TABLE 12 BBB TECHNOLOGY COMPANIES AND CORPORATE PARTNERS/LICENSING
DEALS OR LARGE INVESTMENT WITH LEAD DISEASE TARGET 61
Genzyme Innovates and Sells Technology to Pharmidex 61
DRUG DEVELOPMENT IN THE CNS 62
Multiple Models Must Be Used 62
BBB Is Its Own Site of Investigation 63
Understanding Interactions and Brain Areas as Distinct 64
TABLE 13 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING BBB
TECHNOLOGIES 64
What Values Are Best 66
TABLE 14 FREQUENT DRUG DEVELOPMENT CHALLENGES AND THEIR CLINICAL
EFFECTS 67
PROMISING RESEARCH 67
PROMISING CNS DRUGS THAT ARE LATER STAGE IN THE DEVELOPMENT
PIPELINE FOR POTENTIAL USE WITH BBB TECHNOLOGY 70
Brain Cancer 70
TABLE 15 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2019 71
Anxiety 74
TABLE 16 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2019 74
Dementia 75
TABLE 17 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2019 75
Parkinson's disease 77
TABLE 18 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2019 77
Depression 78
TABLE 19 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2019 78
Personality/Psychiatric Disorders (Schizophrenia/bipolar) 79
TABLE 20 GLOBAL PIPELINE FOR SCHIZOPHRENIA, THROUGH 2019 80
Spinal Cord Injury 80
TABLE 21 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2019 81
Addiction Disorders 81
TABLE 22 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2019 81
Attention Deficit Hyperactivity Disorder (ADHD) 82
TABLE 23 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER,
THROUGH 2019 82
Sleep Disorders 83
TABLE 24 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2019 83
CHAPTER 4 COMPANY PROFILES 86
ABLYNX 86
ADENIOS 87
ANGIOCHEM 87
ARMAGEN TECHNOLOGIES 89
BIOASIS TECHNOLOGIES 90
BRISTOL-MYERS SQUIBB 91
CAPSULUTION PHARMA 92
DAINIPPON SUMITOMO PHARMA 93
ELI LILLY AND COMPANY 93
EUTHYMICS BIOSCIENCE 94
FABRE-KRAMER PHARMACEUTICALS 95
FLOCEL 95
FORUM PHARMACEUTICALS 96
GENZYME 97
INSIGHTEC 97
INTERNATIONAL BRAIN BARRIERS SOCIETY (IBBS) 98
ISIS INNOVATION 98
JANSSEN PHARMACEUTICA 99
H LUNDBECK 100
MEDGENESIS THERAPEUTIX (BIOVAIL LAB) 101
MEDIMMUNE 101
MEDINVENT 102
NANOMERICS 102
NEUROVIVE PHARMACEUTICAL 103
NEUREN PHARMACEUTICALS 103
NSGENE 104
OPTINOSE 106
OSSIANIX 106
OTSUKA AMERICA PHARMACEUTICAL 107
PROTHENA CORP 107
PROTHERAGEN 108
PFIZER 108
PHARMACO-CELL 109
PHARMIDEX 109
RAPTOR PHARMACEUTICAL 111
ROCHE 112
ROYALTY PHARMA 112
SHIRE 113
SANERON CCEL THERAPEUTICS 113
SOLVO BIOTECHNOLOGY 114
SOVICELL 115
TEVA PHARMACEUTICAL INDUSTRIES 115
TO-BBB TECHNOLOGIES 116
TTY BIOPHARM 117
UCB 118
VECT-HORUS 118
XENOPORT 119
XIGEN 120


LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
THROUGH 2019 ($ MILLIONS) 7
TABLE 1 PHARMACEUTICAL DRUGS MARKET BY GEOGRAPHICAL REGION, THROUGH
2017 ($ BILLIONS) 17
TABLE 2 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY,
2013 22
TABLE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH
2019 (NUMBER OF UNITS COMMERCIALIZED) 26
TABLE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY POSSIBLE
CNS INDICATION, 2014 AND 2019 (NUMBER OF UNITS PER INDICATION) 26
TABLE 5 TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS) 27
TABLE 6 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY 44
TABLE 7 KEY BBB TECHNOLOGY PATENTS 48
TABLE 8 SAMPLE OF FINANCIAL DEALS IN CNS THERAPEUTICS IN THE FIVE YEARS
ENDING 2013 54
TABLE 9 SAMPLE OF FINANCIAL DEALS IN BBB TECHNOLOGY RECEIVED THROUGH
PHARMACEUTICAL COMPANY (ESTIMATED, $ MILLIONS) 55
TABLE 10 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND
2019 (NUMBER OF UNITS) 58
TABLE 11 BBB TECHNOLOGY COMPANIES AND RESPECTIVE TECHNOLOGICAL
METHOD 59
TABLE 12 BBB TECHNOLOGY COMPANIES AND CORPORATE PARTNERS/LICENSING
DEALS OR LARGE INVESTMENT WITH LEAD DISEASE TARGET 61
TABLE 13 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING BBB
TECHNOLOGIES 64
TABLE 14 FREQUENT DRUG DEVELOPMENT CHALLENGES AND THEIR CLINICAL
EFFECTS 67
TABLE 15 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2019 71
TABLE 16 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2019 74
TABLE 17 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2019 75
TABLE 18 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2019 77
TABLE 19 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2019 78
TABLE 20 GLOBAL PIPELINE FOR SCHIZOPHRENIA, THROUGH 2019 80
TABLE 21 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2019 81
TABLE 22 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2019 81
TABLE 23 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER,
THROUGH 2019 82
TABLE 24 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2019 83


LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
2012-2019 ($ MILLIONS) 7
FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND
2017 (PERCENT OF GLOBAL SALES) 18
FIGURE 2 EMERGING REGIONS' PHARMACEUTICAL MARKET SHARES COMPARED TO
THE U.S. AND EUROPE, 2017 (ESTIMATED $BILLIONS) 18
FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY REGION,
2019* ($ MILLIONS) 19
FIGURE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY
THERAPEUTIC AREA, 2019* (% OF ALL SALES FROM COMMERCIALIZED DRUGS) 20
FIGURE 5 MOST FREQUENT BBB TARGET AREAS FOR COMPANIES WITH DRUGS IN
CLINICAL DEVELOPMENT, 2019* (%) 21
FIGURE 6 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2012 ($ BILLIONS) 24
FIGURE 7 PARTS OF THE BBB 31
FIGURE 8 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS 32
FIGURE 9 METHODS OF CROSSING THE BBB 42
FIGURE 10 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY TECHNOLOGY TYPE,
2014* (% OF INDUSTRY) 56
FIGURE 11 COMPOSITION OF BBB TECHNOLOGY BY TECHNOLOGY TYPE IN THE
COMMERCIALIZED (THERAPEUTIC DRUG) MARKET, 2019 (% OF MARKET) 56
FIGURE 12 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND
2019 (NUMBER OF UNITS) 58



To order this report: Blood-Brain Barrier Technologies and Global Markets
http://www.reportlinker.com/p0492943/Blood-Brain-Barrier-Technologies-and-Global-Markets.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
The Internet of Things (IoT) is going to require a new way of thinking and of developing software for speed, security and innovation. This requires IT leaders to balance business as usual while anticipating for the next market and technology trends. Cloud provides the right IT asset portfolio to help today’s IT leaders manage the old and prepare for the new. Today the cloud conversation is evolving from private and public to hybrid. This session will provide use cases and insights to reinforce the value of the network in helping organizations to maximize their company’s cloud experience.
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water, are pursuing SmartGrid initiatives that represent one of the more mature examples of SAE. We have spoken with, or attended presentations from, utilities in the United States, South America, Asia and Europe. This session will provide a look at the CREPE drivers for SmartGrids and the solution spaces used by SmartGrids today and planned for the near future. All organizations can learn from SmartGrid’s use of Predictive Maintenance, Demand Prediction, Cloud, Big Data and Customer-facing Dashboards...
IoT is still a vague buzzword for many people. In his session at Internet of @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, will discuss the business value of IoT that goes far beyond the general public's perception that IoT is all about wearables and home consumer services. The presentation will also discuss how IoT is perceived by investors and how venture capitalist access this space. Other topics to discuss are barriers to success, what is new, what is old, and what the future may hold.
Whether you're a startup or a 100 year old enterprise, the Internet of Things offers a variety of new capabilities for your business. IoT style solutions can help you get closer your customers, launch new product lines and take over an industry. Some companies are dipping their toes in, but many have already taken the plunge, all while dramatic new capabilities continue to emerge. In his session at Internet of @ThingsExpo, Reid Carlberg, Senior Director, Developer Evangelism at salesforce.com, to discuss real-world use cases, patterns and opportunities you can harness today.
All major researchers estimate there will be tens of billions devices – computers, smartphones, tablets, and sensors – connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be!
Noted IoT expert and researcher Joseph di Paolantonio (pictured below) has joined the @ThingsExpo faculty. Joseph, who describes himself as an “Independent Thinker” from DataArchon, will speak on the topic of “Smart Grids & Managing Big Utilities.” Over his career, Joseph di Paolantonio has worked in the energy, renewables, aerospace, telecommunications, and information technology industries. His expertise is in data analysis, system engineering, Bayesian statistics, data warehouses, business intelligence, data mining, predictive methods, and very large databases (VLDB). Prior to DataArchon, he served as a VP and Principal Analyst with Constellation Group. He is a member of the Boulder (Colo.) Brain Trust, an organization with a mission “to benefit the Business Intelligence and data management industry by providing pro bono exchange of information between vendors and independent analysts on new trends and technologies and to provide vendors with constructive feedback on their of...
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differentiation that drive front-line agility. We offer four on-ramps to the Digital Enterprise: alignment through collaborative process analysis; transformation through portfolio management; agility through process automation and integration; and visibility through intelligent business operations and big data.
There will be 50 billion Internet connected devices by 2020. Today, every manufacturer has a propriety protocol and an app. How do we securely integrate these "things" into our lives and businesses in a way that we can easily control and manage? Even better, how do we integrate these "things" so that they control and manage each other so our lives become more convenient or our businesses become more profitable and/or safe? We have heard that the best interface is no interface. In his session at Internet of @ThingsExpo, Chris Matthieu, Co-Founder & CTO at Octoblu, Inc., will discuss how these devices generate enough data to learn our behaviors and simplify/improve our lives. What if we could connect everything to everything? I'm not only talking about connecting things to things but also systems, cloud services, and people. Add in a little machine learning and artificial intelligence and now we have something interesting...
Last week, while in San Francisco, I used the Uber app and service four times. All four experiences were great, although one of the drivers stopped for 30 seconds and then left as I was walking up to the car. He must have realized I was a blogger. None the less, the next car was just a minute away and I suffered no pain. In this article, my colleague, Ved Sen, Global Head, Advisory Services Social, Mobile and Sensors at Cognizant shares his experiences and insights.
We are reaching the end of the beginning with WebRTC and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will want to use their existing identities, but these will have credentials already that are (hopefully) irreversibly encoded. In his session at Internet of @ThingsExpo, Peter Dunkley, Technical Director at Acision, will look at how this identity problem can be solved and discuss ways to use existing web identities for real-time communication.
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of WebRTC adoption today, but the potential is limitless when powered by IoT. Attendees will learn real-world benefits of WebRTC and explore future possibilities, as WebRTC and IoT intersect to improve customer service.
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at Internet of @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, will share some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, deploy, and manage applications integrating voice, video and data. He is the co-founder of TeleStax, an Open Source Cloud Communications company that helps the shift from legacy IN/SS7 telco networks to IP-based cloud comms. An early investor in multiple start-ups, he still finds time to code for his companies and contribute to open source projects.
The Internet of Things (IoT) promises to create new business models as significant as those that were inspired by the Internet and the smartphone 20 and 10 years ago. What business, social and practical implications will this phenomenon bring? That's the subject of "Monetizing the Internet of Things: Perspectives from the Front Lines," an e-book released today and available free of charge from Aria Systems, the leading innovator in recurring revenue management.
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges.
There’s Big Data, then there’s really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at 6th Big Data Expo®, Hannah Smalltree, Director at Treasure Data, to discuss how IoT, Big Data and deployments are processing massive data volumes from wearables, utilities and other machines.
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at Internet of @ThingsExpo, Erik Lagerway, Co-founder of Hookflash, will walk through the shifting landscape of traditional telephone and voice services to the modern P2P RTC era of OTT cloud assisted services.
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between conference participants in three dimensional space. This has been shown to significantly improve comprehension and conference efficiency.
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, will discuss single-value, geo-spatial, and log time series data. By focusing on enterprise applications and the data center, he will use OpenTSDB as an example to explain some of these concepts including when to use different storage models.
SYS-CON Events announced today that Gridstore™, the leader in software-defined storage (SDS) purpose-built for Windows Servers and Hyper-V, will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Gridstore™ is the leader in software-defined storage purpose built for virtualization that is designed to accelerate applications in virtualized environments. Using its patented Server-Side Virtual Controller™ Technology (SVCT) to eliminate the I/O blender effect and accelerate applications Gridstore delivers vmOptimized™ Storage that self-optimizes to each application or VM across both virtual and physical environments. Leveraging a grid architecture, Gridstore delivers the first end-to-end storage QoS to ensure the most important App or VM performance is never compromised. The storage grid, that uses Gridstore’s performance optimized nodes or capacity optimized nodes, starts with as few a...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace. These technological reforms have not only changed computers and smartphones, but are also changing the data processing model for all information devices. In particular, in the area known as M2M (Machine-To-Machine), there are great expectations that information with a new type of value can be produced using a variety of devices and sensors saving/sharing data via the network and through large-scale cloud-type data processing. This consortium believes that attaching a huge number of devic...